APEPTICO

APEPTICO is a clinical-stage biotech leveraging a proprietary peptide platform to target epithelial sodium channels (ENaC) for restoring barrier function in damaged tissues. The company's lead asset, solnatide (AP301/TIP), has advanced to Phase II trials for ARDS and has received significant attention and regulatory support for compassionate use in severe COVID-19. Backed by European Union grants and operating as a private entity, APEPTICO is positioning its platform to address high-unmet-need conditions in critical care and inflammation, though it remains pre-revenue and reliant on further clinical and funding milestones.

Platform for developing synthetic therapeutic peptides that mimic natural protein domains, specifically targeting the epithelial sodium channel (ENaC) to restore barrier function and fluid clearance, with additional anti-inflammatory and anti-oxidative effects.

APEPTICO competes in the ARDS space against other biotechs and pharma companies investigating therapies for edema and inflammation, including surfactants, anti-cytokine agents, and stem cell therapies. In inflammation/arthritis, it would face entrenched biologics and novel small molecules. Its unique ENaC-activating peptide mechanism is a differentiating factor but unproven in late-stage trials.